Market Overview:
The global T lymphocyte activation antigen CD86 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of autoimmune diseases, rising geriatric population, and technological advancements in the field of T lymphocyte activation antigen CD86 therapy. However, high cost associated with T lymphocyte activation antigen CD86 therapy may restrain the growth of this market during the forecast period. Based on type, the global T lymphocyte activation antigen CD86 market is segmented into abatacept and biosimilar abatacept. Abatacept is further sub-segmented into KAHR-102 and others. Based on application, the global T lymphocyte activation antigen CD86 market is segmented into musculoskeletal disorders, graft versus host disease (GVHD), lupus nephritis (LN), nephrotic syndrome (NS), and others.
Product Definition:
T lymphocyte activation antigen CD86 is a molecule expressed on the surface of T cells that helps to activate these cells. It is important for the activation of T cells in response to infection or other stimuli.
Abatacept:
Abatacept is a monoclonal antibody that targets interleukin (IL) - 1 receptor and blocks the signaling pathway. IL-1R plays an important role in immune response to infection as well as injury. It is also used for the treatment of rheumatoid arthritis, Crohn's disease, chronic pain due to peripheral neuropathy and diabetic complications.
The drug was approved by the U.
Abatacept Biosimilar:
Abatacept is biosimilar to Rituximab and it's used in the treatment of B-cell malignancies, including Lymphoma and Non-Hodgkin lymphoma. It's mechanism of action involves the binding of Abatacept with CD86 on the B cell surface which leads to its internalization & death.
Application Insights:
The global market for tissue lymphocyte activation antigen CD86 by application is segmented into musculoskeletal disorders, graft-versus-host disease, lupus nephritis, nephrotic syndrome, and others. In 2017, the musculoskeletal disorders segment dominated the global market with a revenue share of over 40%. This can be attributed to increasing incidence of rheumatoid arthritis and osteoarthritis. According to WHO in 2018 osteoarthritis was prevalent in nearly 60 million people globally while rheumatoid arthritis affected around 24 million people. Growing geriatric population is also expected to contribute towards high demand for TLA antigens over the forecast period.
Rising prevalence of chronic diseases such as cancer (excluding non-melanoma skin cancer), autoimmune diseases (excluding Lupus), and infectious diseases is anticipated to boost product demand across various applications during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of players coupled with high R&D investment by them is one of the major factors contributing to its growth. In addition, increasing cases of chronic diseases and rising preference for biologics over traditional ones are also expected to drive this regional market during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to an increase in healthcare expenditure and favorable government initiatives pertaining to immunotherapy treatment for various autoimmune disorders such as lupus nephritis, rheumatoid arthritis, psoriasis, etc. Moreover, growing awareness regarding advanced therapies among patients will boost revenue generation in this region during the estimated time span.
Growth Factors:
- Increasing incidence of autoimmune diseases: The increasing incidence of autoimmune diseases is one of the key growth drivers for the T Lymphocyte Activation Antigen CD86 market. According to a study by the American Autoimmune Related Diseases Association (AARDA), around 50 million Americans are affected by autoimmune diseases, which is approximately 20% of the population. This number is expected to increase in the coming years due to factors such as changing lifestyles and environmental pollution. This will create a high demand for T Lymphocyte Activation Antigen CD86 products and boost the growth of this market.
- Rising awareness about immunotherapy: Immunotherapy has emerged as an effective treatment for various types of cancer in recent years. It involves using substances that stimulate or restore immune system function to fight cancer cells. This has led to an increase in awareness about immunotherapy among patients and healthcare professionals, which is driving its adoption across the world. The T Lymphocyte Activation Antigen CD86 market will benefit from this trend in coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
T Lymphocyte Activation Antigen CD86 Market Research Report
By Type
Abatacept, Abatacept Biosimilar, KAHR-102
By Application
Musculoskeletal Disorders, Graft Versus Host Disease, Lupus Nephritis, Nephrotic Syndrome, Others
By Companies
SBio Inc, Bristol-Myers Squibb Co, KAHR medical Ltd, SBio Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
144
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global T Lymphocyte Activation Antigen CD86 Market Report Segments:
The global T Lymphocyte Activation Antigen CD86 market is segmented on the basis of:
Types
Abatacept, Abatacept Biosimilar, KAHR-102
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Musculoskeletal Disorders, Graft Versus Host Disease, Lupus Nephritis, Nephrotic Syndrome, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- SBio Inc
- Bristol-Myers Squibb Co
- KAHR medical Ltd
- SBio Inc
Highlights of The T Lymphocyte Activation Antigen CD86 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Abatacept
- Abatacept Biosimilar
- KAHR-102
- By Application:
- Musculoskeletal Disorders
- Graft Versus Host Disease
- Lupus Nephritis
- Nephrotic Syndrome
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the T Lymphocyte Activation Antigen CD86 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
T lymphocyte activation antigen CD86 is a protein that is found on the surface of some T cells. This protein helps to activate the T cell and help it fight against infection or disease.
Some of the major companies in the t lymphocyte activation antigen cd86 market are SBio Inc, Bristol-Myers Squibb Co, KAHR medical Ltd, SBio Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 T Lymphocyte Activation Antigen CD86 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 T Lymphocyte Activation Antigen CD86 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 T Lymphocyte Activation Antigen CD86 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the T Lymphocyte Activation Antigen CD86 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global T Lymphocyte Activation Antigen CD86 Market Size & Forecast, 2020-2028
4.5.1 T Lymphocyte Activation Antigen CD86 Market Size and Y-o-Y Growth
4.5.2 T Lymphocyte Activation Antigen CD86 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Abatacept
5.2.2 Abatacept Biosimilar
5.2.3 KAHR-102
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Musculoskeletal Disorders
6.2.2 Graft Versus Host Disease
6.2.3 Lupus Nephritis
6.2.4 Nephrotic Syndrome
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global T Lymphocyte Activation Antigen CD86 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 T Lymphocyte Activation Antigen CD86 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Abatacept
9.6.2 Abatacept Biosimilar
9.6.3 KAHR-102
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Musculoskeletal Disorders
9.10.2 Graft Versus Host Disease
9.10.3 Lupus Nephritis
9.10.4 Nephrotic Syndrome
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Abatacept
10.6.2 Abatacept Biosimilar
10.6.3 KAHR-102
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Musculoskeletal Disorders
10.10.2 Graft Versus Host Disease
10.10.3 Lupus Nephritis
10.10.4 Nephrotic Syndrome
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Abatacept
11.6.2 Abatacept Biosimilar
11.6.3 KAHR-102
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Musculoskeletal Disorders
11.10.2 Graft Versus Host Disease
11.10.3 Lupus Nephritis
11.10.4 Nephrotic Syndrome
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Abatacept
12.6.2 Abatacept Biosimilar
12.6.3 KAHR-102
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Musculoskeletal Disorders
12.10.2 Graft Versus Host Disease
12.10.3 Lupus Nephritis
12.10.4 Nephrotic Syndrome
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Abatacept
13.6.2 Abatacept Biosimilar
13.6.3 KAHR-102
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Musculoskeletal Disorders
13.10.2 Graft Versus Host Disease
13.10.3 Lupus Nephritis
13.10.4 Nephrotic Syndrome
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 T Lymphocyte Activation Antigen CD86 Market: Competitive Dashboard
14.2 Global T Lymphocyte Activation Antigen CD86 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 SBio Inc
14.3.2 Bristol-Myers Squibb Co
14.3.3 KAHR medical Ltd
14.3.4 SBio Inc
